Given its role in chemoresistance, targeting GSH has emerged as a potential strategy to enhance the efficacy of cancer treatment. Several approaches are under investigation:
GSH Depletion: Agents like BSO (buthionine sulfoximine) that inhibit GSH synthesis are being studied to sensitize cancer cells to chemotherapy. Combination Therapy: Combining GSH-depleting agents with traditional chemotherapy or radiotherapy to improve treatment outcomes. Targeted Delivery: Using nanoparticles or other delivery systems to specifically reduce GSH levels in cancer cells while sparing normal cells.
